Through an acquisition completed on November 3, 2006, Andrx Corporation became a wholly-owned subsidiary of Watson Pharmaceuticals, Inc. Andrx Corporation is engaged in the development and commercialization of bioequivalent versions of controlled-release brand name pharmaceuticals, using its proprietary drug delivery technologies, and bioequivalent versions of specialty, niche and immediate-release pharmaceutical products, including oral contraceptives. The Company also develops and distributes brand name or proprietary controlled-release formulations of existing immediate-release or controlled-release drugs. It manufactures and sells bioequivalent versions of Cardizem CD, Dilacor XR, Ventolin, Glucophage, K-Dur and Naprelan. In its brand program, Andrx sells and markets Altocor, its first internally developed brand product, as well as brand products it has acquired or licensed from third parties. It also distributes pharmaceutical products manufactured by third parties, primarily generics, to independent pharmacies, pharmacy chains, pharmacy buying groups and, to a lesser extent, physicians' offices.
